<DOC>
	<DOCNO>NCT01709864</DOCNO>
	<brief_summary>The study serve determine whether treatment patient stable , symptomatic Chronic Obstructive Pulmonary Disease ( COPD ) investigational drug NVA237 efficient safe . The efficacy safety drug test placebo treatment . The primary criterion ass efficacy difference serial lung function measurement patient treat 12 week NVA237 versus receive placebo treatment 12 week . A serial lung function measurement ( FEV1 test ) conduct `` area curve '' measure ability breathe .</brief_summary>
	<brief_title>NVA237 Versus Placebo 12-week Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients stable , symptomatic Chronic Obstructive Pulmonary Disease ( COPD ) airflow obstruction level 2 3 accord current Global initiative chronic Obstructive Lung Disease ( GOLD ) strategy ( 2011 ) . 2 . Patients Forced Expiratory Volume one second ( FEV1 ) ≥ 30 % &lt; 80 % predict normal , FEV1/ Forced Vital Capacity ( FVC ) &lt; 0.70 measure 45 min inhalation 84 µg ipratropium bromide . 3 . Current exsmokers least 10 cigarette pack year smoke history . Exclusion criterion : 1 . Patients history long QT syndrome , prolong QTc measure screening , patient clinically significant ECG abnormality screening . 2 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 3 . Pregnant nursing ( lactate ) woman . Women childbearing potential unless use effective method contraception . 4 . Patients judgment investigator , would potential risk enrol study . 5 . Patients clinically significant concomitant disease screening , include limit clinically significant laboratory abnormality , clinically significant renal , cardiovascular , neurological , endocrine , immunological , psychiatric , gastrointestinal , hepatic , hematological abnormality , uncontrolled diabetes , could interfere assessment efficacy safety study treatment . 6 . Patients body mass index ( BMI ) 40 kg/m2 . 7 . Patients contraindicate treatment , history reactions/ hypersensitivity anticholinergic agent , long short act beta2 agonist , sympathomimetic amine . 8 . Patients history asthma , onset symptom prior age 40 year , patient high blood eosinophil count screening . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Anticholinergic</keyword>
	<keyword>Antimuscarinic</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>LAMA</keyword>
	<keyword>Lung Disease</keyword>
	<keyword>Lung Diseases , Obstructive</keyword>
	<keyword>Lung Function</keyword>
	<keyword>Muscarinic receptor antagonist</keyword>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
</DOC>